PredictImmune appoints Steven S. Martin as non-executive director
Managing Partner of Paxton Advisors, LLC and ex-CEO of Blue Cross and Blue Shield of Nebraska, appointed with immediate effect
Cambridge, UK, 05 November: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to welcome Steven S. Martin to its board.
Mr Martin is managing partner of Paxton Advisors, LLC a business advisory and consulting firm based in Omaha, Nebraska. Previously, Mr Martin was President and Chief Executive Officer for Blue Cross and Blue Shield of Nebraska (BCBSNE), leading the company’s executive management team for over 16 years and serving as a member of the board of directors from March 2002 until March 2018. BCBSNE, an independent licensee of the Blue Cross and Blue Shield Association, is the largest health insurance and health benefits administrator serving Nebraskans. BCBSNE is wholly owned by Good Life Partners, Inc., a not-for-profit mutual insurance holding company and is an independent licensee of the Blue Cross and Blue Shield Association. Mr Martin also served as the founding board chair of Think Whole Person Healthcare, the largest primary care clinic and pharmacy in Nebraska.
Steven S Martin, Co-founder, Paxton Advisors, LLC, commented: “I am excited to be joining the PredictImmune board and look forward to working with the team. The company has developed pioneering testing that adds precision in the selection of treatment options for immune-mediated diseases, beginning with IBD. This will increase the speed for selecting the right treatments for the right individuals, saving time, avoiding waste, and improving outcomes.”
Paul Kinnon, CEO, PredictImmune added: “I am delighted to welcome Steve to the board. His experience with BCBSNE and extensive knowledge of the healthcare market in the United States will be critically important in helping PredictImmune optimise both product awareness and reimbursement strategies for PredictSURE® IBD as we work with our partners, KSL, to launch the product in the US. Steve’s input will be pivotal in ensuring this ground-breaking prognostic test is made available to US IBD patients in a timely manner to drive the potential of improved outcomes and overall wellness for these patients in the coming months.”
When: 21st – 23rd October 2019 | Venue: Fira Barcelona Grand Via, Barcelona, Spain | Stand 86
UEG Week provides a unique educational experience and opportunity to network with top minds in the Gastroenterology & Hepatology communities from around the globe. UEG Week 2019 is the United European Gastroenterology’s annual conference and enables you to hear about current developments in disciplines ranging from gastroenterology and Hepatology to Liver Transplantation, Gi Endoscopy and IBD. UEG Week is the place to be for clinicians and researchers who will work closely with politicians & policy-makers to drive future developments.
The scientific programme includes all aspects of our specialty, ranging from basic science to clinical practice guidelines. A world class faculty will gather for UEG week to present the latest research and state-of-the art clinical practice.
Dr Paul Lyons
Founder & VP Platform Development
Dr Karen Hills
Director of Medical Affairs